Gallic Acid and Neuroprotection: A Critical Review of Preclinical Evidence and Mechanisms

Gallic acid (GA), chemically designated 3,4,5-trihydroxybenzoic acid, is a low-molecular-weight phenolic acid that occurs naturally in a broad range of plants and plant-derived foods [1,2]. It may be present in free form or associated with tannins and other polyphenolic constituents and can be released during hydrolysis of these compounds [1,3].Botanical sources include grape seeds, rose flowers, sumac, oak, witch hazel, and several medicinal plants. The compound has also been found in materials such as Ocimum gratissimum, Solenostemma argel, and white tea [3,4,6,7].

The chemical structure of GA contains three hydroxyl groups attached to a benzoic acid nucleus. This arrangement contributes to its redox properties and ability to interact with reactive species [1,2,5]. Oxidative stress is a recurring feature of many chronic diseases and is particularly relevant to the nervous system because neurons have high metabolic requirements and comparatively limited capacity for regeneration. Excessive reactive oxygen and nitrogen species can damage lipids, proteins, nucleic acids, membranes, mitochondria, and signaling systems. Consequently, compounds capable of modifying redox imbalance have attracted substantial attention as potential neuroprotective agents.

The biological activity of GA extends beyond direct antioxidant effects. Experimental literature has associated the compound with anti-inflammatory, antimicrobial, anticancer, hepatoprotective, antidiabetic, cardioprotective, and neuroprotective actions [1,2,4,5,8]. These effects appear to involve several cellular pathways rather than a single pharmacological target. In neuronal systems, the interaction between oxidative stress, inflammation, mitochondrial dysfunction, and apoptosis is especially important. A compound capable of influencing several of these processes may therefore have advantages over an approach directed toward only one downstream event.

The present review focuses specifically on the neurobiological profile of GA. Evidence concerning Alzheimer's disease (AD), Parkinson's disease (PD), anxiety-related behavior, sedation, neuroinflammation, apoptosis, intracellular signaling, preclinical models, therapeutic possibilities, pharmacokinetic limitations, and safety is considered. Because the available literature includes studies of purified GA as well as GA-containing preparations and chemically related polyphenols, these forms of evidence are distinguished where appropriate.

2. NATURAL SOURCES AND GENERAL BIOLOGICAL PROPERTIES

2.1 Natural sources

GA is distributed among numerous botanical materials and dietary products. Its occurrence in plants is influenced by species, tissue, growth conditions, processing, and the chemical form in which the compound is stored. It may be encountered as a free phenolic acid or as a structural component of hydrolysable tannins. Sources reported in the literature include grapes, rose flowers, sumac, oak, witch hazel, white tea, and medicinal plants such as O. gratissimum and S. argel [1,3,4,6,7].

The broad distribution of GA has encouraged investigation of both dietary exposure and pharmacological applications. Nevertheless, the presence of GA in a plant extract does not necessarily indicate that the biological activity of the extract is attributable exclusively to GA. Other phenolics, flavonoids, tannins, terpenoids, and volatile constituents may contribute to the observed response. For this reason, studies using purified GA are particularly valuable when establishing a direct structure-activity relationship.

2.2 General biological properties

Antioxidant activity is among the most extensively investigated properties of GA. Its phenolic structure permits interaction with reactive species and may contribute to preservation of cellular redox balance [1,2,5]. In experimental systems, antioxidant responses have been evaluated through changes in enzymes such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), as well as markers including glutathione (GSH), malondialdehyde (MDA), and thiobarbituric acid reactive substances (TBARS).

GA has also been associated with modulation of inflammatory processes. Experimental reports describe effects on inflammatory cytokines and intracellular pathways involved in inflammatory gene expression [5,8]. Anti-inflammatory activity is particularly relevant to neuroprotection because prolonged activation of microglia and persistent release of inflammatory mediators can amplify neuronal injury.

Other reported biological effects include antimicrobial and anticancer activities. GA and GA-containing formulations have been investigated in several cancer models, while broader reviews have described hepatoprotective, antidiabetic, cardioprotective, and other pharmacological effects [2,4,5,7]. These observations demonstrate the pharmacological versatility of GA but should not be interpreted as evidence that all reported activities are clinically established.

3. MECHANISMS OF NEUROPROTECTION BY GALLIC ACID

Neurodegenerative and neuropsychiatric disorders are multifactorial conditions. Oxidative stress, neuroinflammation, impaired trophic signaling, mitochondrial dysfunction, and apoptosis can interact and reinforce one another. The available experimental evidence suggests that GA may influence several of these processes simultaneously.

3.1 Alzheimer's disease

Alzheimer's disease is a progressive neurodegenerative disorder characterized clinically by deterioration of memory and other cognitive functions and pathologically by changes that include amyloid pathology, neurofibrillary alterations, synaptic dysfunction, and neuronal loss. Oxidative stress and neuroinflammation are also implicated in disease progression. Current management strategies can provide symptomatic or disease-modifying benefits in selected patients, but substantial unmet therapeutic needs remain.

Brain-derived neurotrophic factor (BDNF) is an important regulator of neuronal differentiation, synaptic plasticity, neuronal survival, and cognitive function. The hippocampus is particularly relevant to BDNF-dependent processes because of its role in learning and memory. Experimental work cited in the source manuscript indicates that GA at 50 and 100 mg/kg increased hippocampal BDNF in rats exposed to trimethyltin (TMT), while also modifying hippocampal TNF-α [9]. These findings suggest that GA may influence both neurotrophic and inflammatory responses.

In an intracerebroventricular streptozotocin model of AD-like impairment, GA at 30 mg/kg was reported to improve passive-avoidance and memory-related performance and to enhance antioxidant defenses, including SOD, CAT, and GPx, while reducing TBARS in hippocampal tissue. No reference in the retained set directly supports this specific streptozotocin finding; it should be re-sourced from the original manuscript before use. These results are consistent with the hypothesis that preservation of antioxidant capacity may contribute to cognitive protection.

The relationship between these mechanisms is important. Oxidative stress can impair neuronal signaling and promote inflammatory responses, whereas inflammatory mediators can further increase oxidative damage. GA may therefore provide benefit through simultaneous regulation of redox status, trophic signaling, and inflammatory pathways. However, the experimental models described above do not reproduce the complete pathology of human AD, and their findings should be regarded as preclinical evidence.

3.2 Parkinson's disease

Parkinson's disease is a progressive neurological disorder in which degeneration of dopaminergic neurons in the substantia nigra contributes to motor manifestations such as tremor, rigidity, and bradykinesia. Experimental models have demonstrated relationships among dopaminergic dysfunction, oxidative stress, mitochondrial injury, and neuronal apoptosis.

GA has been investigated in several experimental paradigms relevant to PD [11,12]. In a reserpine-induced model, GA at 13.5 and 40.5 mg/kg reduced vacuous chewing movements in rats [10]. A separate experimental paradigm involving tacrine and haloperidol reported reductions in vacuous chewing movements and catalepsy following GA administration at 150 mg/kg. No reference in the retained set directly supports this tacrine/haloperidol finding; it should be re-sourced from the original manuscript before use. These behavioral effects are consistent with the possibility that GA can modify abnormalities associated with dopaminergic dysfunction, although the models are not equivalent to idiopathic PD in humans.

6-hydroxydopamine (6-OHDA) is widely used to produce experimental dopaminergic injury. The source manuscript reports that GA concentrations of 0.25–2.5 μg/mL attenuated changes in Nrf2, Keap-1, caspase-3, BDNF, phosphorylated CREB, Bax, and Bcl-2 in a cellular model. In an in vivo 6-OHDA model, GA administered at 50, 100, and 200 mg/kg was associated with improved memory-related performance and reduced biochemical indicators of oxidative stress, including MDA and TBARS, with increases in total thiol and GPx reported. Neither of these 6-OHDA findings is supported by a reference in the retained set; both should be re-sourced from the original manuscript before use.

Together, these findings support the view that the anti-Parkinsonian potential of GA may involve more than symptomatic modulation. Its effects on antioxidant defenses and apoptotic signaling could contribute to preservation of neuronal function. Nevertheless, the precise contribution of each pathway and the relevance of the reported doses to achievable human exposure require further study.

3.3 Anxiety-related effects

Anxiety is regulated by interconnected neural systems involving serotonergic, noradrenergic, dopaminergic, and GABAergic signaling. Chronic stress can also influence hippocampal structure and function and has been associated with cognitive impairment and vulnerability to neuropsychiatric disease.

Several animal studies have reported anxiolytic-like effects of GA. In mice exposed to chronic restraint stress, GA at 5, 10, and 20 mg/kg was associated with reduced anxiety-related behavior and changes in antioxidant status, including increased total antioxidant capacity and reduced MDA [15]. In another investigation, GA produced effects in the elevated plus maze that were consistent with anxiolytic-like activity and were associated with serotonergic mechanisms involving the 5-HT1A receptor [16].

Brain-targeted GA nanoparticles have also been investigated. GA nanoparticles and GA administered at 10 mg/kg were associated with reduced plasma nitrite concentrations in Swiss mice [17]. In unstressed and stressed mice, GA at 5, 10, and 20 mg/kg produced anxiolytic-like effects; the reported findings suggested involvement of neuronal nitric oxide synthase in unstressed animals and inducible nitric oxide synthase together with corticosterone modulation in stressed animals [18].

These studies suggest that GA may affect anxiety-related behavior through interactions among oxidative, serotonergic, and nitrergic systems. However, behavioral changes in animal models cannot by themselves establish clinical anxiolytic efficacy.

3.4 Dose-dependent sedative effects

Sedation is characterized by reduced central nervous system activity and decreased behavioral arousal. The behavioral profile of GA appears to depend on dose. The source literature reports anxiolytic-like activity at lower doses, whereas a dose of 500 mg/kg was associated with reduced locomotor activity in rats. No reference in the retained set supports this specific 500 mg/kg finding; it should be re-sourced from the original manuscript before use. Reduced locomotion can reflect sedation, but it may also arise from motor impairment or other nonspecific effects. Consequently, interpretation should consider the full behavioral battery rather than relying on a single measure.

The dose dependence of GA is important for therapeutic development. A compound that improves anxiety-related behavior at one exposure level but reduces locomotion at a substantially higher exposure illustrates the need for pharmacokinetic and dose-response studies before extrapolation to human use.

4. MOLECULAR BASIS OF GA-MEDIATED NEUROPROTECTION

4.1 Anti-inflammatory mechanisms

Neuroinflammation involves coordinated responses of microglia, astrocytes, neurons, endothelial cells, and other components of the central nervous system. Activated microglia can release cytokines such as TNF-α, IL-1β, and IL-6 and can generate reactive species that further compromise neuronal integrity.

GA has been investigated as a modulator of inflammatory signaling. Evidence discussed in the source manuscript links GA and related polyphenolic mechanisms to NF-κB and MAPK signaling, pathways that regulate inflammatory gene expression [14]. Suppression of these pathways may decrease production of inflammatory mediators, including COX-2 and iNOS.

The Nrf2/HO-1 pathway provides an additional connection between antioxidant and inflammatory responses. Activation of Nrf2 promotes expression of cytoprotective and antioxidant genes such as HO-1 and NQO1. By strengthening endogenous antioxidant defenses, GA may reduce the redox conditions that promote inflammatory activation. The combined influence on oxidative and inflammatory processes may therefore be more important than either activity considered in isolation.

It is important, however, to distinguish direct GA evidence from evidence involving other polyphenols. Some studies investigate sulforaphane, sargachromenol, Moringa preparations, or other non-GA compounds.

4.2 Anti-apoptotic effects

Programmed cell death is an important component of neuronal loss. Mitochondrial dysfunction, oxidative damage, DNA injury, and activation of caspases can converge on apoptotic pathways. Proteins of the Bcl-2 family regulate mitochondrial membrane integrity, while cytochrome c release can initiate caspase activation.

Experimental studies summarized in the source manuscript associate GA with preservation of anti-apoptotic Bcl-2 and attenuation of pro-apoptotic mediators such as Bax and caspase-3. Other reported signaling components include caspase-9, p53, and cleaved PARP. Through modulation of these proteins, GA may limit mitochondrial disruption and downstream execution of apoptosis.

The anti-apoptotic effect should nevertheless be interpreted in the context of the experimental system. Concentration, cell type, exposure duration, oxidative stimulus, and whether GA is used alone or as part of a preparation can all influence the observed response.

4.3 Nrf2/HO-1 signaling

Nrf2 is a central regulator of cellular antioxidant and cytoprotective responses. Under conditions that favor Nrf2 activation, the transcription factor can accumulate in the nucleus and promote expression of genes involved in antioxidant defense and detoxification, including HO-1 and NQO1.

The source literature proposes that GA enhances Nrf2-associated antioxidant signaling and thereby counteracts oxidative injury [14]. In neuronal models, strengthening this endogenous defense system could help maintain redox balance and reduce downstream activation of inflammatory and apoptotic pathways.

The relevance of Nrf2 to GA is therefore not limited to direct radical scavenging. Activation of a transcriptional antioxidant program may produce a more sustained cellular response. Whether this mechanism is sufficient to explain GA-mediated neuroprotection in vivo, however, remains to be established.

4.4 NF-κB signaling

NF-κB is a major regulator of inflammatory gene transcription. In its inactive state, NF-κB is retained in the cytoplasm through interaction with inhibitory proteins such as IκBα. Following appropriate activating signals, IκBα phosphorylation and degradation permit NF-κB to translocate to the nucleus and regulate inflammatory genes.

GA has been reported in the reviewed literature to inhibit NF-κB-associated signaling, potentially reducing expression of cytokines and inflammatory enzymes. This mechanism provides a link between GA exposure and suppression of neuroinflammatory responses.

Because several references cited in the original manuscript concern other natural products rather than GA itself, those references have been removed here; the strength of the evidence should be described carefully, and direct experiments using purified GA are preferable for establishing a specific GA-NF-κB relationship.

4.5 MAPK signaling

Mitogen-activated protein kinases, including ERK, JNK, and p38, participate in cellular responses to stress, inflammation, differentiation, and apoptosis. Excessive or prolonged activation of these pathways can contribute to neuronal injury.

The source literature associates GA with reduced activation of MAPK signaling and downstream inflammatory responses [14]. Such modulation could reduce expression of stress-responsive and pro-inflammatory genes and may interact with the Nrf2 and NF-κB systems.

The significance of MAPK modulation is therefore best viewed as part of an interconnected signaling network rather than an isolated GA target.

4.6 Integrated mechanism

The available evidence supports a multi-target model in which GA may simultaneously influence oxidative stress, inflammatory signaling, trophic support, and apoptosis [13]. Nrf2/HO-1 signaling can enhance endogenous antioxidant defenses; inhibition of NF-κB and MAPK pathways can reduce inflammatory signaling; and regulation of Bcl-2 family proteins and caspases can limit apoptosis. Changes in BDNF-related signaling may additionally support neuronal plasticity and survival.

This integrated model provides a mechanistic rationale for investigating GA in disorders in which oxidative stress and inflammation interact. It also highlights an important limitation: demonstration of pathway modulation does not necessarily prove that the pathway is the primary cause of the observed behavioral or neuroprotective effect. Future studies using selective inhibitors, genetic approaches, target engagement measurements, and clinically relevant models will be required to establish causality.

5. PRECLINICAL EVIDENCE

5.1 In vitro evidence

Cell-based studies provide a useful platform for determining whether GA can protect neurons or neuronal-like cells from defined insults. Oxidative and nitrosative stress can cause lipid peroxidation, mitochondrial dysfunction, protein modification, DNA damage, and apoptosis. Polyphenolic compounds have frequently been investigated for their capacity to attenuate these processes.

The source manuscript notes that direct in vitro evidence specifically using purified GA in neuronal cultures is comparatively limited and also discusses studies of rosmarinic acid, carnosic acid, plant extracts, and related polyphenolics tested on other compounds rather than GA; those references have been removed from this version. These studies are mechanistically informative but should be kept separate from direct GA experiments. A study of rosmarinic acid or carnosic acid, for example, demonstrates the neuroprotective potential of those compounds rather than proving the same effect for GA.

Network pharmacology and extract-based studies may also identify antioxidant components or pathways associated with neuroprotection. Such evidence can generate hypotheses, but direct experimental validation is necessary to determine whether GA itself is responsible for the predicted effect.

Future in vitro investigations should therefore use purified, chemically characterized GA and report concentration, exposure time, cell type, viability assay, oxidative stimulus, and molecular endpoints. Dose-response relationships should be established, particularly because higher concentrations of phenolic compounds can sometimes become cytotoxic.

5.2 In vivo evidence

Animal models provide information that cannot be obtained from cell culture alone, particularly regarding behavior, systemic exposure, tissue distribution, and integrated physiological responses.

In a murine model of post-stroke depression, GA administration was associated with improvement in depressive-like behavior together with changes in antioxidant parameters, including SOD, CAT, TBARS, and GSH [14]. These findings suggest that attenuation of oxidative imbalance may contribute to functional improvement following ischemic injury.

The source manuscript also cited work involving polyphenolic constituents of Acacia nilotica in arsenic-induced neurotoxicity; this reference has been removed here because it does not test GA specifically. Such evidence can be relevant to the broader antioxidant concept but should not automatically be interpreted as a direct GA study unless GA was specifically isolated, quantified, and tested.

Similarly, the source manuscript's reference to stem-cell therapy in Huntington's disease models has been removed for the same reason. Such work demonstrates the importance of restoring neuronal function but does not constitute evidence for GA, and is better used, if at all, as contextual background illustrating the therapeutic relevance of neuronal survival and repair pathways rather than as a GA citation.

6. POTENTIAL THERAPEUTIC APPLICATIONS

6.1 Alzheimer's disease

The experimental findings discussed above suggest that GA may be relevant to AD-related mechanisms involving oxidative stress, neuroinflammation, trophic signaling, and cognitive dysfunction. GA has produced improvements in memory-related endpoints in selected animal models and has influenced antioxidant parameters in hippocampal tissue [9,19].

However, studies involving epigallocatechin-3-gallate (EGCG) should not be equated with studies of GA. EGCG is a distinct catechin containing a gallate group and has its own pharmacological and pharmacokinetic characteristics. Evidence from EGCG can support the broader plausibility of gallated polyphenols in neuroprotection but cannot establish efficacy of purified GA.

6.2 Parkinson's disease

In PD models, GA has been associated with reduced abnormal movements, improved behavioral outcomes, and attenuation of oxidative stress [10,11,12]. These effects provide a rationale for further investigation, particularly in relation to dopaminergic neuronal survival and mitochondrial function.

A major challenge is determining whether the doses producing benefit in animals can be achieved safely in humans. Pharmacokinetic studies should therefore accompany efficacy studies rather than being performed only after therapeutic claims have been made.

6.3 Ischemic stroke and post-stroke depression

Ischemic brain injury produces oxidative and inflammatory responses that can extend tissue damage beyond the initial ischemic event. The reported effects of GA in a post-stroke depression model, including changes in antioxidant defenses and behavior [14], suggest possible utility in this setting.

The potential role of GA in stroke should nevertheless be considered exploratory. Important outcomes for future studies include infarct volume, neurological deficit scores, inflammatory biomarkers, oxidative injury, blood-brain barrier integrity, and long-term functional recovery.

6.4 Neuropsychiatric applications

The anxiolytic-like effects described in experimental models suggest another possible application. However, reduction of anxiety-related behavior may occur through several mechanisms, including sedation or changes in general locomotor activity. Therefore, future studies should include complementary behavioral tests that distinguish specific anxiolysis from nonspecific motor suppression.

7. BIOAVAILABILITY AND PHARMACOKINETIC CHALLENGES

A promising pharmacological mechanism does not guarantee therapeutic effectiveness. GA faces important pharmacokinetic challenges related to absorption, metabolism, distribution, stability, and tissue exposure [3]. Rapid metabolic transformation and clearance can reduce the amount of unchanged compound available systemically and may limit exposure at target tissues.

For neuroprotective applications, brain exposure is especially important. Demonstration of antioxidant activity in vitro at a particular concentration is meaningful only if comparable exposure can be achieved in the nervous system without unacceptable toxicity. Therefore, pharmacokinetic studies should measure plasma and, where feasible, brain concentrations and relate them to pharmacodynamic endpoints.

Drug-delivery approaches such as nanoparticles, conjugates, and other carrier systems have been proposed to improve stability, bioavailability, and tissue targeting [17]. Brain-targeted GA nanoparticles have also been investigated in the context of antianxiety-like activity. These approaches are promising but require careful characterization of particle size, loading efficiency, release behavior, biodistribution, stability, and safety.

An important future objective is to establish a quantitative exposure-response relationship for GA. Such information would help determine whether the concentrations used in cellular studies and the doses used in animal studies are pharmacologically realistic.

8. SAFETY AND TOXICITY

8.1 General considerations

The source manuscript describes GA as having a relatively favorable preclinical safety profile but also acknowledges limited human toxicity data. This distinction is important. Absence of obvious toxicity in selected animal experiments does not establish safety for chronic human administration.

Safety assessment should consider dose, duration, route of administration, formulation, species, age, sex, metabolic status, and concomitant substances. In addition, GA derivatives and GA-containing herbal preparations should not be treated as pharmacologically identical to purified GA.

8.2 In vitro toxicity

The source material reports that GA produced little effect on neutrophil viability below 100 μM and that a co-culture model involving Nerve-2A and BV-2 cells showed no major viability effect at 5–50 μM, whereas concentrations of 100 μM or above were associated with toxicity.

These observations emphasize the importance of concentration. A compound may be protective within a particular exposure range but harmful at higher concentrations. Consequently, future studies should report both protective and toxic concentration ranges and calculate appropriate therapeutic windows.

8.3 In vivo toxicity

The original manuscript summarizes several animal studies reporting relatively high tolerated doses of GA, including oral administration in mice and acute toxicity observations in zebrafish and rabbits. Some experiments reported no major behavioral, morphological, or hematological changes at specified doses.

These findings are useful for preliminary safety assessment but should not be interpreted as definitive evidence that GA is non-toxic. Acute and short-term studies provide limited information about chronic administration, reproductive effects, developmental toxicity, organ-specific toxicity, interactions, and susceptible populations.

Long-term studies should therefore include comprehensive hematological, biochemical, histopathological, neurological, reproductive, and behavioral assessments. Where possible, toxicokinetic measurements should be incorporated so that adverse findings can be related to systemic exposure.

9. FUTURE RESEARCH DIRECTIONS

Several research gaps must be addressed before GA can be considered a clinically credible neuroprotective agent.

First, purified GA should be studied using standardized experimental systems. Investigations involving extracts or GA-rich preparations are valuable for natural-product research but cannot replace studies in which the concentration and purity of GA are known.

Second, mechanistic claims require stronger causal validation. Changes in Nrf2, NF-κB, MAPK, BDNF, Bax, Bcl-2, or caspases should ideally be tested with pathway-specific inhibitors, activators, genetic manipulation, or target-engagement experiments.

Third, pharmacokinetic and pharmacodynamic studies should be integrated. Researchers need to know whether neuroprotective concentrations observed in vitro can be achieved in the brain and how formulation changes alter exposure.

Fourth, long-term safety requires greater attention. Chronic neurological disorders may require prolonged treatment, making acute toxicity data insufficient.

Fifth, more clinically relevant models are needed. Disease models should reproduce important pathological features, and studies should include both sexes where scientifically appropriate. Behavioral findings should be complemented by histological, biochemical, molecular, and functional endpoints.

Sixth, clinical translation requires carefully designed human studies. Early-phase trials should establish tolerability, pharmacokinetics, dose proportionality, and relevant biomarkers before larger efficacy trials are undertaken.

Finally, interactions between GA and existing therapeutic agents deserve investigation. If GA is ultimately developed as an adjunct rather than a replacement therapy, pharmacokinetic and pharmacodynamic interactions will become important determinants of its clinical utility.

CONCLUSION

Gallic acid is a naturally occurring phenolic compound with a broad experimental pharmacological profile. The neuroprotective evidence reviewed in the source manuscript indicates that GA can influence several biological processes relevant to neuronal injury, including oxidative stress, inflammation, apoptosis, trophic signaling, and behavioral dysfunction.

In Alzheimer's-related models, GA has been associated with improvements in memory-related outcomes and preservation of antioxidant defenses. In experimental Parkinsonian models, it has reduced abnormal behavioral responses and oxidative injury. Studies of anxiety-related behavior additionally indicate possible involvement of serotonergic and nitrergic mechanisms. At the molecular level, Nrf2/HO-1, NF-κB, MAPK, and mitochondrial apoptotic signaling provide plausible frameworks for understanding these effects.

The multi-target profile of GA is scientifically attractive because neurodegenerative disorders are not driven by a single pathological pathway. Nevertheless, the current evidence is predominantly preclinical. Important uncertainties remain concerning brain exposure, pharmacokinetics, dose optimization, chronic toxicity, mechanism-specific causality, and human efficacy.

GA should therefore be regarded as a promising experimental neuroprotective candidate rather than an established clinical treatment. Future work that combines rigorous mechanistic validation, standardized formulations, pharmacokinetic characterization, long-term safety assessment, and well-designed clinical studies will determine whether its broad preclinical activity can be translated into a useful therapeutic intervention.

REFERENCES

1. Gao J, Hu J, Hu D, Yang X. A Role of Gallic Acid in Oxidative Damage Diseases: A Comprehensive Review. Natural Product Communications. 2019;14(8):1934578X19874174. doi:10.1177/1934578X19874174.
2. Khan BA, Mahmood T, Menaa F, Shahzad Y, Yousaf AM, Hussain T, Ray SD. New perspectives on the efficacy of gallic acid in cosmetics & nanocosmeceuticals. Current pharmaceutical design. 2018 Dec 1;24(43):5181-7.
3. Ugbogu OC, Emmanuel O, Agi GO, Ibe C, Ekweogu CN, Ude VC, Uche ME, Nnanna RO, Ugbogu EA. A review on the traditional uses, phytochemistry, and pharmacological activities of clove basil (Ocimum gratissimum L.). Heliyon. 2021 Nov 1;7(11).
4. Kahkeshani N, Farzaei F, Fotouhi M, Alavi SS, Bahramsoltani R, Naseri R, Momtaz S, Abbasabadi Z, Rahimi R, Farzaei MH, Bishayee A. Pharmacological effects of gallic acid in health and diseases: A mechanistic review. Iranian journal of basic medical sciences. 2019 Mar;22(3):225.
5. Elsanhoty RM, Soliman MS, Khidr YA, Hassan GO, Hassan AR, Aladhadh M, Abdella A. Pharmacological activities and characterization of phenolic and flavonoid compounds in Solenostemma argel extract. Molecules. 2022 Nov 22;27(23):8118.
6. Rosman R, Saifullah B, Maniam S, et al. Improved Anticancer Effect of Magnetite Nanocomposite Formulation of Gallic Acid (Fe3O4-PEG-GA) Against Lung, Breast and Colon Cancer Cells. Nanomaterials. 2018;8(2):83.
7. Sung B, Hwang D, Baek A, Yang B, Lee S, Park J, Kim E, Kim M, Lee E, Chang Y. Gadolinium-based magnetic resonance theranostic agent with gallic acid as an anti-neuroinflammatory and antioxidant agent. Antioxidants. 2024 Feb 5;13(2):204.
8. Kalinowska M, Go??biewska E, ?widerski G, M?czy?ska-Wielgosz S, Lewandowska H, Pietryczuk A, Cudowski A, Astel A, ?wis?ocka R, Samsonowicz M, Z?owodzka AB. Plant-derived and dietary hydroxybenzoic acids—A comprehensive study of structural, anti-/pro-oxidant, lipophilic, antimicrobial, and cytotoxic activity in MDA-MB-231 and MCF-7 cell lines. Nutrients. 2021 Sep 4;13(9):3107.
9. Baziyar Y, Edalatmanesh MA, Hosseini SA, Zar A. The effects of endurance training and gallic acid on BDNF and TNF-a in male rats with Alzheimer. International Journal of Applied Exercise Physiology. 2016;5(4).
10. Reckziegel P, Peroza LR, Schaffer LF, Ferrari MC, de Freitas CM, Bürger ME, Fachinetto R. Gallic acid decreases vacuous chewing movements induced by reserpine in rats. Pharmacology Biochemistry and Behavior. 2013 Mar 1;104:132-7.
11. Kasture VS, Katti SA, Mahajan D, Wagh R, Mohan M, Kasture SB. Antioxidant and antiparkinson activity of gallic acid derivatives. Pharmacologyonline. 2009;1:385-95.Bhuia MS, Rahaman MM, Islam T, et al. Neurobiological effects of gallic acid: current perspectives. Chinese Medicine. 2023;18(1):27. doi:10.1186/s13020-023-00735-7.
12. Shabani S, Rabiei Z, Amini-Khoei H. Exploring the multifaceted neuroprotective actions of gallic acid: A review. International Journal of Food Properties. 2020 Jan 1;23(1):736-52.
13. Nabavi SF, Habtemariam S, Di Lorenzo A, Sureda A, Khanjani S, Nabavi SM, Daglia M. Post-stroke depression modulation and in vivo antioxidant activity of gallic acid and its synthetic derivatives in a murine model system. Nutrients. 2016 Apr 28;8(5):248.
14. Salehi A, Rabiei Z, Setorki M. Effect of gallic acid on chronic restraint stress-induced anxiety and memory loss in male BALB/c mice. Iranian journal of basic medical sciences. 2018 Dec;21(12):1232.
15. Mansouri MT, Soltani M, Naghizadeh B, Farbood Y, Mashak A, Sarkaki A. A possible mechanism for the anxiolytic-like effect of gallic acid in the rat elevated plus maze. Pharmacology Biochemistry and Behavior. 2014 Feb 1;117:40-6.
16. Nagpal K, Singh SK, Mishra DN. Optimization of brain targeted gallic acid nanoparticles for improved antianxiety-like activity. International journal of biological macromolecules. 2013 Jun 1;57:83-91.
17. Dhingra D, Chhillar R, Gupta A. Antianxiety-like activity of gallic acid in unstressed and stressed mice: possible involvement of nitriergic system. Neurochemical Research. 2012 Mar;37(3):487-94.
18. Hajipour S, Sarkaki A, Farbood Y, Eidi A, Mortazavi P, Valizadeh Z. Effect of gallic acid on dementia type of Alzheimer disease in rats: electrophysiological and histological studies. Basic and clinical neuroscience. 2016 Apr;7(2):97.